AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15583776 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-bag system
Number of subjects: 33
Study 15583776 — intervention group
Group type: COMPARATOR
Intervention: One-bag system
Number of subjects: 33
Study 11758701 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralization instruction
Number of subjects: 0
Study 11758701 — intervention group
Group type: COMPARATOR
Intervention: No neutralization instruction
Number of subjects: 0
Study 9156108 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenchay Aphasia Screening Test
Number of subjects: 10
Study 9156108 — intervention group
Group type: EXPERIMENTAL
Intervention: Request to write 'name and address'
Number of subjects: 10
Study 7892971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% plain bupivacaine
Number of subjects: 42
Study 7892971 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 42
Study 3657889 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of aspartame per kilogram of body weight
Number of subjects: 40
Study 3657889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3657889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 40
Study 29902133 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT vaccine (Priorix, GSK)
Number of subjects: 869
Study 29902133 — intervention group
Group type: COMPARATOR
Intervention: MMR II vaccine (control; M-M-R II, Merck&Co Inc.)
Number of subjects: 869
Study 28298558 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 165
Study 28298558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 165
Study 26285695 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG (Thymoglobulin®)
Number of subjects: 183
Study 26285695 — intervention group
Group type: COMPARATOR
Intervention: basiliximab
Number of subjects: 183
Study 26285695 — intervention group
Group type: EXPERIMENTAL
Intervention: rATG
Number of subjects: 183
Study 23059130 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical coupling information (ECI) available
Number of subjects: 40
Study 21062996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serp-1 (5 μg/kg)
Number of subjects: 48
Study 21062996 — intervention group
Group type: EXPERIMENTAL
Intervention: Serp-1 (15 μg/kg)
Number of subjects: 48
Study 21062996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21062996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Number of subjects: 48
Study 18187530 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0343 0.75 mg
Number of subjects: 12
Study 18187530 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0343 0.25 mg
Number of subjects: 12
Study 18187530 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 12
Study 18187530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17010856 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional capsular tension ring (CTR)
Number of subjects: 70
Study 17010856 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed foldable equator ring (CFER)
Number of subjects: 70
Study 14732977 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Number of subjects: 34
Study 14732977 — intervention group
Group type: COMPARATOR
Intervention: PVP chemotherapy
Number of subjects: 34
Study 11032585 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 159
Study 9014295 — intervention group
Group type: COMPARATOR
Intervention: DHEAS, 50 mg po bid for 4 days, administered as an adjuvant to tetanus vaccination.
Number of subjects: 133
Study 9014295 — intervention group
Group type: COMPARATOR
Intervention: DHEAS administered immediately before and 24 hours after influenza vaccination.
Number of subjects: 133
Study 1362613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine (200 mg 4 times daily)
Number of subjects: 138
Study 1362613 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSC (500 mg 4 times daily)
Number of subjects: 138
Study 1362613 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily) and Cysteine
Number of subjects: 138
Study 1362613 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily) and MMSC
Number of subjects: 138
Study 1362613 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily) alone
Number of subjects: 138
Study 3161176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% foscarnet cream
Number of subjects: 86
Study 3161176 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 86
Study 29578732 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition (low masculinity feedback, n = 22)
Number of subjects: 65
Study 29578732 — intervention group
Group type: COMPARATOR
Intervention: Control condition (high masculinity feedback, n = 22)
Number of subjects: 65
Study 29578732 — intervention group
Group type: EXPERIMENTAL
Intervention: Undermine condition (low masculinity feedback with undermining information, n = 21)
Number of subjects: 65
Study 27998448 — intervention group
Group type: COMPARATOR
Intervention: docetaxel/cisplatin (Control)
Number of subjects: 124
Study 27998448 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin (Arm 1)
Number of subjects: 124
Study 27998448 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/cisplatin (Arm 2)
Number of subjects: 124
Study 27998448 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel alone (Arm 3)
Number of subjects: 124
Study 24758167 — intervention group
Group type: EXPERIMENTAL
Intervention: Be smart against cancer (BSAC) program
Number of subjects: 235
Study 24758167 — intervention group
Group type: COMPARATOR
Intervention: Wait-control group
Number of subjects: 235
Study 22024203 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive module
Number of subjects: 36
Study 22024203 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (Control)
Number of subjects: 36
Study 20702806 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR; 0.5 l/day; 5.2 mmol of NO(3)(‐)/day)
Number of subjects: 8
Study 20702806 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 8
Study 18469091 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554
Study 18469091 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (ESO) 20 mg once daily (can be increased to 40 mg once daily or 20 mg twice daily)
Number of subjects: 554
Study 15939025 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded response procedure
Number of subjects: 0
Study 15939025 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit condition
Number of subjects: 0
Study 15939025 — intervention group
Group type: EXPERIMENTAL
Intervention: Process dissociation procedure
Number of subjects: 0
Study 12014516 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IU/m2/day of growth hormone (GH)
Number of subjects: 29
Study 12014516 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IU/m2/day of growth hormone (GH)
Number of subjects: 29
Study 12014516 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group (2 IU/m2/day)
Number of subjects: 29
Study 12014516 — intervention group
Group type: COMPARATOR
Intervention: High-dose group (4 IU/m2/day)
Number of subjects: 29
Study 10081129 — intervention group
Group type: COMPARATOR
Intervention: Sublingual glycine application in daily dose of 1-2 g for 5 days, starting within the first 6 hours of stroke development.
Number of subjects: 200
Study 10081129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 200
Study 7583388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of antibiotics regardless of ANC; initial treatment with ceftazidime +/- vancomycin for a median length of treatment of 3 days
Number of subjects: 32
Study 2246580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Number of subjects: 50
Study 2246580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 50
Study 462159 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 36
Study 462159 — intervention group
Group type: COMPARATOR
Intervention: Primary radiotherapy
Number of subjects: 36
Study 31422924 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for CABG
Number of subjects: 1858
Study 31422924 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for PCI
Number of subjects: 1858
Study 31422924 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for renal failure in CABG
Number of subjects: 1858
Study 31422924 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for renal failure in PCI
Number of subjects: 1858
Study 31064965 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily life-based physical activity enhancement program with one-on-one counseling, customized text messages, exercise diary, and mobile pedometer for 12 weeks
Number of subjects: 58
Study 31064965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 58
Study 28267011 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol with ascorbic acid
Number of subjects: 167
Study 28267011 — intervention group
Group type: COMPARATOR
Intervention: Oral sulfate solution
Number of subjects: 167
Study 26554839 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal home-visiting program using psychologists
Number of subjects: 440
Study 26554839 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 440
Study 23045243 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe patellofemoral osteoarthritis (PFOA)
Number of subjects: 167
Study 23045243 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe PFOA
Number of subjects: 167
Study 23045243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild PFOA
Number of subjects: 167
Study 20500120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 35
Study 20500120 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 35
Study 19303137 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 1 year
Number of subjects: 713
Study 19303137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 19303137 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 713
Study 17540908 — intervention group
Group type: EXPERIMENTAL
Intervention: Information programme
Number of subjects: 742
Study 17540908 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 742
Study 17540908 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 742
Study 11057005 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0
Study 11057005 — intervention group
Group type: EXPERIMENTAL
Intervention: Invalid cue validity (S1)
Number of subjects: 0
Study 8647360 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (n = 18)
Number of subjects: 36
Study 8647360 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral etoposide (n = 18)
Number of subjects: 36
Study 1596044 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin (DR) combination therapy
Number of subjects: 95
Study 1596044 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline-streptomycin (DS) combination therapy
Number of subjects: 95
Study 1596044 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin (DR) combination therapy excluding spondylitis patients
Number of subjects: 95
Study 1596044 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline-streptomycin (DS) combination therapy excluding spondylitis patients
Number of subjects: 95
Study 6208807 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 9
Study 6208807 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% plasmaprotein solution (PPS)
Number of subjects: 9
Study 30125349 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2640
Number of subjects: 16
Study 30125349 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 16
Study 30191370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 0
Study 30191370 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 0
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' A colorectal cancer
Number of subjects: 1537
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' B colorectal cancer
Number of subjects: 1537
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' C colorectal cancer
Number of subjects: 1537
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Right colon tumors
Number of subjects: 1537
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Left colon tumors
Number of subjects: 1537
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal tumors
Number of subjects: 1537
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial stage influence on postrecurrence survival
Number of subjects: 1537
Study 26135689 — intervention group
Group type: EXPERIMENTAL
Intervention: Site of primary influence on postrecurrence survival
Number of subjects: 1537
Study 24909625 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrier frequency of 500 Hz, modulated at 40 Hz, intensity of 95 dBA
Number of subjects: 83
Study 24909625 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrier frequencies of 250, 500, and 1000 Hz, modulated at 20, 37, 40, 43, 70, 77, and 80 Hz, intensity of 95 dBA
Number of subjects: 83
Study 24909625 — intervention group
Group type: COMPARATOR
Intervention: Group of normal hearers
Number of subjects: 83
Study 22843115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) (4 × 5‐min 220 mm Hg bilateral leg occlusion)
Number of subjects: 13
Study 22843115 — intervention group
Group type: COMPARATOR
Intervention: Control (C) (4 × 5‐min 20 mm Hg bilateral leg occlusion)
Number of subjects: 13
Study 20189927 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord grape juice (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Number of subjects: 77
Study 20189927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Number of subjects: 77
Study 18758386 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole 18 mg/kg twice daily
Number of subjects: 101
Study 18758386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 16190387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 1.2 x 10(4) U/kg (half dose intravenously after induction, half in primary solution)
Number of subjects: 22
Study 16190387 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 22
Study 16190387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 1.2 x 10(4) U/kg
Number of subjects: 22
Study 12208645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release ascorbic acid (3000 mg/day)
Number of subjects: 81
Study 12208645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10624701 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum α-tocopherol
Number of subjects: 204
Study 8786878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical management strategies for uterine fibromyomata
Number of subjects: 0
Study 8786878 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative temporizing measures
Number of subjects: 0
Study 1957553 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 with TRH
Number of subjects: 10
Study 1957553 — intervention group
Group type: COMPARATOR
Intervention: TRH alone
Number of subjects: 10
Study 1957553 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH alone
Number of subjects: 10
Study 30511292 — intervention group
Group type: EXPERIMENTAL
Intervention: Diario della Salute program
Number of subjects: 2630
Study 30511292 — intervention group
Group type: COMPARATOR
Intervention: Regular curriculum (Control)
Number of subjects: 2630
Study 28730886 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 m incremental shuttle walk test (ISWT)
Number of subjects: 15
Study 25980582 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tailored text messaging for 90 days
Number of subjects: 48
Study 25980582 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 24820711 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate (CaS) placed into the postextraction sockets
Number of subjects: 30
Study 24820711 — intervention group
Group type: COMPARATOR
Intervention: Obliterative suture only
Number of subjects: 30
Study 22441104 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment group (ITG) with Peg IFNa-2a and ADV
Number of subjects: 160
Study 22441104 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (STG) with Peg IFNa-2a monotherapy
Number of subjects: 160
Study 22441104 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment group (ITG)
Number of subjects: 160
Study 22441104 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (STG)
Number of subjects: 160
Study 20430207 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced CsA blood level (RE group)
Number of subjects: 25
Study 20430207 — intervention group
Group type: COMPARATOR
Intervention: Standard CsA blood level (SE group)
Number of subjects: 25
Study 20430207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 18575222 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 202
Study 18575222 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene 0.1% cream
Number of subjects: 202
Study 15855501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alamifovir single doses (0.2 to 80 mg), subset receiving 20 mg in a fed state
Number of subjects: 0
Study 15855501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alamifovir multiple doses (2.5 to 15 mg twice daily for 15 days)
Number of subjects: 0
Study 15855501 — intervention group
Group type: COMPARATOR
Intervention: Food intake (fed state)
Number of subjects: 0
Study 15855501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alamifovir and its metabolites
Number of subjects: 0
Study 14563518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study 10471425 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherothrombotic strokes
Number of subjects: 1272
Study 10471425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes
Number of subjects: 1272
Study 10471425 — intervention group
Group type: EXPERIMENTAL
Intervention: Strokes of other/unknown mechanism
Number of subjects: 1272
Study 10471425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar strokes
Number of subjects: 1272
Study 10471425 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infarcts
Number of subjects: 1272
Study 10471425 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between stroke subtype and time of symptom onset
Number of subjects: 1272
Study 8951781 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P alone
Number of subjects: 682
Study 8951781 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P with hydroxyurea maintenance
Number of subjects: 682
Study 8951781 — intervention group
Group type: COMPARATOR
Intervention: Non radio-mimetic agents (hydroxyurea or pipobroman)
Number of subjects: 682
Study 8951781 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P-treated cases (excluding skin cancers)
Number of subjects: 682
Study 8951781 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P and hydroxyurea as maintenance
Number of subjects: 682
Study 8951781 — intervention group
Group type: COMPARATOR
Intervention: Non radio-mimetic agents (hydroxyurea or pipobroman) in relatively young cases
Number of subjects: 682
Study 8951781 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 682
Study 8951781 — intervention group
Group type: COMPARATOR
Intervention: Pipobroman-treated cases
Number of subjects: 682
Study 1937996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) given i.v. 1, 2 and 3 h before surgery
Number of subjects: 24
Study 1937996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ciprofloxacin)
Number of subjects: 24
Study 6754067 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 52
Study 6754067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF
Number of subjects: 52
Study 30472195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular digital model (DM) registration using the mucogingival junction as the reference
Number of subjects: 12
Study 30472195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular digital model (DM) registration
Number of subjects: 12
Study 28054966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened coffee
Number of subjects: 46
Study 28054966 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-energy orange juice (OJ)
Number of subjects: 46
Study 28054966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (LFM)
Number of subjects: 46
Study 28054966 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 46
Study 28054966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free milk
Number of subjects: 46
Study 28054966 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 46
Study 24423575 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention for heavy drinkers
Number of subjects: 103
Study 24423575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 103
Study 23672851 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast (335 kcals)
Number of subjects: 0